RE:RE:RE:RE:RE:RE:RE:Exciting update!! SF... good summary. And I am not saying Philip did nothing right in the past 13 years. The clinical studies, the safety of the pouch, conformal coating and identifying other applications... he certainly deserves credit.
But the business side / commercial needs someone else. A closer. I don't think Philip has it in him. Too many "near misses" in the last year.
I also disagree with some of your statements. Non-dilutive financing?! Compare the float between July 2020 and now. But you are correct that there does not appear to be convertible debt.
LifeSci? There was a minor blip on the share price where they were announced. But evidence of tangible results is lacking. I.e. where are the institutional investors? Why did they not pick up the slack on Jan 10 sell-off? Where is the new money?
Is Philip making efforts? Yes. Are the efforts translating to results? Not so much.
Like I said... good guy. Thank you for your services. But time for a change.